Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.

Today, we focus on MYND Life Sciences (MYND.C), a Canadian developer of psilocybin-assisted solutions for neurological conditions such as depression and Alzheimers utilizing non-psychedelic molecules to treat the neuroinflammation associated behind the physical manifestations of said conditions.

Enjoy!